In the latest session, Cardlytics Inc (NASDAQ: CDLX) closed at $14.10 up 7.96% from its previous closing price of $13.06. In other words, the price has increased by $+1.04 from its previous closing price. On the day, 3072344 shares were traded.
Ratios:
For a deeper understanding of Cardlytics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 1.97 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Craig Hallum on March 15, 2024, Upgraded its rating to Buy and sets its target price to $18 from $10 previously.
On November 29, 2023, Lake Street started tracking the stock assigning a Buy rating and target price of $13.
Wells Fargo Downgraded its Equal Weight to Underweight on September 08, 2022, whereas the target price for the stock was revised from $14 to $13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 18 ’24 when SOSIN CLIFFORD bought 350,000 shares for $13.40 per share. The transaction valued at 4,689,685 led to the insider holds 6,023,676 shares of the business.
SOSIN CLIFFORD bought 311,715 shares of CDLX for $4,274,174 on Mar 15 ’24. The 10% Owner now owns 5,673,676 shares after completing the transaction at $13.71 per share. On Mar 04 ’24, another insider, Temsamani Karim Saad, who serves as the Chief Executive Officer of the company, sold 34,515 shares for $7.89 each. As a result, the insider received 272,323 and left with 327,298 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDLX now has a Market Capitalization of 575.62M and an Enterprise Value of 749.89M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 4.16. Its current Enterprise Value per Revenue stands at 2.43 whereas that against EBITDA is -7.57.
Stock Price History:
The Beta on a monthly basis for CDLX is 1.36, which has changed by 274.21% over the last 52 weeks, in comparison to a change of 31.54% over the same period for the S&P500. Over the past 52 weeks, CDLX has reached a high of $19.57, while it has fallen to a 52-week low of $2.57. The 50-Day Moving Average of the stock is 7.35, while the 200-Day Moving Average is calculated to be 9.87.
Shares Statistics:
For the past three months, CDLX has traded an average of 1.14M shares per day and 2.84M over the past ten days. A total of 44.11M shares are outstanding, with a floating share count of 40.76M. Insiders hold about 7.59% of the company’s shares, while institutions hold 66.21% stake in the company. Shares short for CDLX as of Feb 29, 2024 were 4.36M with a Short Ratio of 3.83, compared to 4.16M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.10% and a Short% of Float of 12.85%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.34, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.06, with high estimates of $0.1 and low estimates of -$0.25.
Analysts are recommending an EPS of between $0.56 and -$0.63 for the fiscal current year, implying an average EPS of -$0.03. EPS for the following year is $0.77, with 2 analysts recommending between $1.03 and $0.52.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $71.69M this quarter.It ranges from a high estimate of $72.4M to a low estimate of $70.99M. As of the current estimate, Cardlytics Inc’s year-ago sales were $64.33M, an estimated increase of 11.40% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $340.7M, while the lowest revenue estimate was $335M, resulting in an average revenue estimate of $337.79M. In the same quarter a year ago, actual revenue was $309.2M, up 9.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $381.67M in the next fiscal year. The high estimate is $385.25M and the low estimate is $375.97M. The average revenue growth estimate for next year is up 13.00% from the average revenue estimate for this year.
